Clinical Trial Update: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating AO-176 as monotherapy and in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• AO-176
• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)

Snippet

Sponsor: Arch Oncology | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED